We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04592341
Recruitment Status : Active, not recruiting
First Posted : October 19, 2020
Last Update Posted : January 20, 2023
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This is a Phase II, multicenter, open-label, single arm, PD study in participants with early (prodromal to mild) AD to evaluate the effect of a once weekly (Q1W) dosing regimen of gantenerumab on deposited amyloid as measured by change from baseline to Week 104 (primary) and Week 208 in brain amyloid positron emission tomography (PET). The administration of gantenerumab as a single injection of Q1W will be investigated in this study, to simplify the dosing regimen for participants.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: Gantenerumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 192 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Pharmacodynamic Effects of Once Weekly Administration of Gantenerumab in Participants With Early (Prodromal to Mild) Alzheimer's Disease
Actual Study Start Date : November 18, 2020
Actual Primary Completion Date : January 11, 2023
Estimated Study Completion Date : March 13, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Gantenerumab
Participants will receive gantenerumab by subcutaneous (SC) injection at a dose of 120 mg every 4 weeks (Q4W) for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg every 2 weeks (Q2W) for another 12 weeks, followed by the target dose 255 mg once weekly (Q1W) for up to Week 103. Participants who complete Week 104 visit will be given an option to take part in 2-year extension of the study to receive gantenerumab 255 mg Q1W for up to Week 207.
Drug: Gantenerumab
Gantenerumab will be administered by SC injection at a dose of 120 mg Q4W for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg Q2W for another 12 weeks, followed by the target dose 255 mg Q1W for up to Week 103 and an optional dose of 255 mg Q1W for up to Week 207.

Primary Outcome Measures :
  1. Change from Baseline in Deposited Amyloid as Measured by Brain Amyloid PET Centiloid (CL) Levels [ Time Frame: Up to Week 104 ]

Secondary Outcome Measures :
  1. Responses to Home Administration Questionnaire [ Time Frame: Up to Week 208 ]
    The home administration questionnaire will capture confidence, ease of use, convenience, and overall satisfaction.

  2. Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to Week 224 ]
  3. Change in the Columbia-Suicide Severity Rating Scale (C-SSRS) Score [ Time Frame: Up to Week 208 ]
    The C-SSRS is an assessment tool used to assess the lifetime suicidality of a patient (C-SSRS at baseline) as well as any new instances of suicidality (C-SSRS since last visit). The structured interview prompts recollection of suicidal ideation, including the intensity of the ideation, behavior, and attempts with actual or potential lethality.

  4. Percentage of Participants with Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI) [ Time Frame: Up to Week 208 ]
  5. Percentage of Participants with Amyloid-Related Imaging Abnormalities-Haemosiderin deposition (ARIA-H) Confirmed by Magnetic Resonance Imaging (MRI) [ Time Frame: Up to Week 208 ]
  6. Percentage of Participants with Injection-Site Reactions (ISR) [ Time Frame: 24 hours after study drug administration, up to Week 208 ]
    Injection reactions (local and systemic) are defined as adverse events that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.

  7. Percentage of Participants with Anti-Drug Antibodies to Gantenerumab [ Time Frame: Up to Week 224 ]
  8. Plasma Concentration of SC Gantenerumab at specified timepoints [ Time Frame: Up to Week 224 ]
  9. Change in Brain Amyloid Based on Different Dosing Frequency [ Time Frame: Up to Week 208 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Probable Alzheimer's Disease (AD) dementia or prodromal AD.
  • Availability of a reliable study partner (non-professional caregiver) who accepts to participate in study procedure throughout the study duration
  • The participant should be capable of completing all aspects of study assessments including MRI, clinical genotyping, and PET imaging, either alone or with the help of the study partner (non-professional caregiver).
  • Adequate visual and auditory acuitysufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted).
  • Evidence of AD pathological process, as confirmed by amyloid PET scan by qualitative read by the core/central PET laboratory.
  • Prodromal or mild symptomatology, as defined by a screening Mini-Mental State Examination (MMSE) score >/=22 and Clinical Dementia Rating global score (CDR-GS) of 0.5 or 1.0, as well as a clinical dementia rating (CDR) memory domain score >/=0.5.
  • If the participant is receiving symptomatic AD medications, a stable dosing regimen for at least 3 months prior to screening and until start of study treatment.
  • Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug.
  • Agreement not to participate in other research studies for the duration of this trial, unless these are related Roche-sponsored non-interventional studies.
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods hat result in a failure rate of < 1% per year during the treatment period and for at least 16 weeks after the final dose of study drug.

Exclusion Criteria:

  • Any evidence of a condition other than AD that may affect cognition.
  • History or presence of clinically evident systemic vascular disease that in the opinion of the investigator has the potential to affect cognitive function.
  • History or presence of clinically evident cerebrovascular disease.
  • History or presence of posterior reversible encephalopathy syndrome.
  • History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack.
  • History of severe, clinically significant CNS trauma.
  • History or presence of intracranial mass that could potentially impair cognition.
  • Presence of infections that affect brain function or history of infections that resulted in neurologic sequelae.
  • History or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits.
  • History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder.
  • At risk for suicide in the opinion of the investigator.
  • Alcohol and/or substance abuse or dependants in past 2 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04592341

Show Show 34 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT04592341    
Other Study ID Numbers: WN29722
2020-001384-87 ( Registry Identifier: EudraCT )
First Posted: October 19, 2020    Key Record Dates
Last Update Posted: January 20, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Supporting Materials: Study Protocol

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders